Advanced Accelerator Applications
Develops diagnostic and therapeutic products in the field of molecular nuclear medicine.
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 22 % | 15 % | 16 % | 18 % | 7 % | 15 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (19 %) | 8 % | (4 %) | 50 % | 87 % | 79 % | 71 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (20 %) | 22 % | (43 %) | 46 % | 73 % | 17 % | 54 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Advanced Accelerator Applications (AAA) specializes in developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology. Operating within the nuclear medicine sector, AAA focuses on creating innovative treatments for cancer patients, particularly those with advanced and metastatic conditions. The company serves healthcare providers and patients, offering solutions that enhance diagnostic accuracy and therapeutic outcomes. AAA's business model revolves around research and development, clinical trials, and commercialization of their radiopharmaceutical products. Revenue is generated through the sale of these specialized therapies and imaging agents, often in collaboration with healthcare institutions and pharmaceutical companies. The market AAA operates in is highly specialized, targeting oncology indications with unmet medical needs. The company is a subsidiary of Novartis, leveraging its parent company's resources and expertise to advance its mission.
Keywords: radioligand therapy, nuclear medicine, oncology, precision imaging, cancer care, radiopharmaceuticals, advanced prostate cancer, metastatic cancer, clinical trials, Novartis